2021 Q2 Form 10-Q Financial Statement
#000159075021000070 Filed on August 12, 2021
Income Statement
Concept | 2021 Q2 | 2020 Q2 |
---|---|---|
Revenue | $1.090M | $168.0K |
YoY Change | 548.81% | -93.32% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $6.523M | $2.710M |
YoY Change | 140.7% | -5.24% |
% of Gross Profit | ||
Research & Development | $12.57M | $3.836M |
YoY Change | 227.55% | -55.39% |
% of Gross Profit | ||
Depreciation & Amortization | $25.00K | $64.00K |
YoY Change | -60.94% | -36.0% |
% of Gross Profit | ||
Operating Expenses | $19.09M | $6.542M |
YoY Change | 191.78% | -42.89% |
Operating Profit | -$18.00M | -$6.374M |
YoY Change | 182.37% | -28.72% |
Interest Expense | $34.00K | -$60.00K |
YoY Change | -156.67% | -220.0% |
% of Operating Profit | ||
Other Income/Expense, Net | $34.00K | $33.00K |
YoY Change | 3.03% | -88.0% |
Pretax Income | -$17.96M | -$6.440M |
YoY Change | 178.94% | -27.64% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$17.96M | -$6.435M |
YoY Change | 179.16% | -27.66% |
Net Earnings / Revenue | -1648.07% | -3830.36% |
Basic Earnings Per Share | -$2.21 | -$1.82 |
Diluted Earnings Per Share | -$2.21 | -$1.82 |
COMMON SHARES | ||
Basic Shares Outstanding | 8.107M shares | 3.538M shares |
Diluted Shares Outstanding | 8.107M shares | 3.538M shares |
Balance Sheet
Concept | 2021 Q2 | 2020 Q2 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $109.3M | $30.60M |
YoY Change | 257.19% | -30.3% |
Cash & Equivalents | $27.70M | $30.58M |
Short-Term Investments | $81.60M | $0.00 |
Other Short-Term Assets | $4.110M | $1.700M |
YoY Change | 141.76% | -55.26% |
Inventory | ||
Prepaid Expenses | ||
Receivables | $2.051M | $248.0K |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $115.5M | $32.52M |
YoY Change | 255.04% | -32.36% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $298.0K | $379.0K |
YoY Change | -21.37% | -41.87% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $97.00K | $1.000K |
YoY Change | 9600.0% | -98.0% |
Total Long-Term Assets | $2.740M | $964.0K |
YoY Change | 184.23% | 37.32% |
TOTAL ASSETS | ||
Total Short-Term Assets | $115.5M | $32.52M |
Total Long-Term Assets | $2.740M | $964.0K |
Total Assets | $118.2M | $33.49M |
YoY Change | 253.0% | -31.36% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $2.392M | $286.0K |
YoY Change | 736.36% | -76.79% |
Accrued Expenses | $14.15M | $3.020M |
YoY Change | 368.54% | -23.47% |
Deferred Revenue | $288.0K | |
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | $3.400M | |
YoY Change | -15.0% | |
Total Short-Term Liabilities | $16.83M | $6.723M |
YoY Change | 150.33% | -26.51% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $5.400M |
YoY Change | -100.0% | -12.9% |
Other Long-Term Liabilities | $1.167M | $211.0K |
YoY Change | 453.08% | |
Total Long-Term Liabilities | $1.167M | $211.0K |
YoY Change | 453.08% | |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $16.83M | $6.723M |
Total Long-Term Liabilities | $1.167M | $211.0K |
Total Liabilities | $19.29M | $12.31M |
YoY Change | 56.65% | -19.75% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$315.3M | -$182.7M |
YoY Change | 72.58% | 24.44% |
Common Stock | $86.00K | $531.0K |
YoY Change | -83.8% | 71.29% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $98.91M | $21.17M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $118.2M | $33.49M |
YoY Change | 253.0% | -31.36% |
Cashflow Statement
Concept | 2021 Q2 | 2020 Q2 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$17.96M | -$6.435M |
YoY Change | 179.16% | -27.66% |
Depreciation, Depletion And Amortization | $25.00K | $64.00K |
YoY Change | -60.94% | -36.0% |
Cash From Operating Activities | -$14.63M | -$6.790M |
YoY Change | 115.46% | -5.3% |
INVESTING ACTIVITIES | ||
Capital Expenditures | -$49.00K | $0.00 |
YoY Change | -100.0% | |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | -$11.15M | $0.00 |
YoY Change | -100.0% | |
Cash From Investing Activities | -$11.20M | $0.00 |
YoY Change | -100.0% | |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 7.051M | 1.260M |
YoY Change | 459.6% | -3250.0% |
NET CHANGE | ||
Cash From Operating Activities | -14.63M | -6.790M |
Cash From Investing Activities | -11.20M | 0.000 |
Cash From Financing Activities | 7.051M | 1.260M |
Net Change In Cash | -18.78M | -5.530M |
YoY Change | 239.64% | -195.02% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$14.63M | -$6.790M |
Capital Expenditures | -$49.00K | $0.00 |
Free Cash Flow | -$14.58M | -$6.790M |
YoY Change | 114.74% | -4.9% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001590750 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Viridian Therapeutics, Inc./DE | ||
CY2019 | us-gaap |
Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member | |
CY2019 | us-gaap |
Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member | |
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
CY2021Q2 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent | |
CY2020Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent | |
CY2021Q2 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent | |
CY2021Q2 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-06-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-36483 | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-1187261 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
203 Crescent Street, Bldg. 17, Suite 102B | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Waltham | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02453 | ||
dei |
City Area Code
CityAreaCode
|
617 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
272-4600 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.01 par value per share | ||
dei |
Trading Symbol
TradingSymbol
|
VRDN | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2021Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
9587155 | shares |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
27704000 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
45897000 | USD |
CY2021Q2 | us-gaap |
Short Term Investments
ShortTermInvestments
|
81597000 | USD |
CY2020Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
81742000 | USD |
CY2021Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4110000 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1972000 | USD |
CY2021Q2 | mgen |
Unbilled Contracts Receivable Related Party Current
UnbilledContractsReceivableRelatedPartyCurrent
|
2051000 | USD |
CY2020Q4 | mgen |
Unbilled Contracts Receivable Related Party Current
UnbilledContractsReceivableRelatedPartyCurrent
|
0 | USD |
CY2021Q2 | us-gaap |
Assets Current
AssetsCurrent
|
115462000 | USD |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
129611000 | USD |
CY2021Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
298000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
309000 | USD |
CY2021Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1567000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
478000 | USD |
CY2021Q2 | mgen |
Other Assets Related Party Noncurrent
OtherAssetsRelatedPartyNoncurrent
|
778000 | USD |
CY2020Q4 | mgen |
Other Assets Related Party Noncurrent
OtherAssetsRelatedPartyNoncurrent
|
856000 | USD |
CY2021Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
97000 | USD |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1000 | USD |
CY2021Q2 | us-gaap |
Assets
Assets
|
118202000 | USD |
CY2020Q4 | us-gaap |
Assets
Assets
|
131255000 | USD |
CY2021Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2392000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
670000 | USD |
CY2021Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
14150000 | USD |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9703000 | USD |
CY2021Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
288000 | USD |
CY2020Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
301000 | USD |
CY2021Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16830000 | USD |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10674000 | USD |
CY2021Q2 | mgen |
Other Liabilities Related Party Noncurrent
OtherLiabilitiesRelatedPartyNoncurrent
|
1293000 | USD |
CY2020Q4 | mgen |
Other Liabilities Related Party Noncurrent
OtherLiabilitiesRelatedPartyNoncurrent
|
501000 | USD |
CY2021Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1167000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
43000 | USD |
CY2021Q2 | us-gaap |
Liabilities
Liabilities
|
19290000 | USD |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
11218000 | USD |
CY2021Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2021Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2021Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
8608886 | shares |
CY2021Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
8608886 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
4231135 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
4231135 | shares |
CY2021Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
86000 | USD |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
42000 | USD |
CY2021Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
259786000 | USD |
CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
218089000 | USD |
CY2021Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-12000 | USD |
CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-8000 | USD |
CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-315311000 | USD |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-278887000 | USD |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
98912000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
120037000 | USD |
CY2021Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
118202000 | USD |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
131255000 | USD |
CY2021Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
1090000 | USD |
CY2020Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
168000 | USD |
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2541000 | USD | |
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
996000 | USD | |
CY2021Q2 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
12565000 | USD |
CY2020Q2 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
3836000 | USD |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
26371000 | USD | |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
9939000 | USD | |
CY2021Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6523000 | USD |
CY2020Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2706000 | USD |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12683000 | USD | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5429000 | USD | |
CY2021Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
19088000 | USD |
CY2020Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
6542000 | USD |
us-gaap |
Operating Expenses
OperatingExpenses
|
39054000 | USD | |
us-gaap |
Operating Expenses
OperatingExpenses
|
15368000 | USD | |
CY2021Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17998000 | USD |
CY2020Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6374000 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-36513000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14372000 | USD | |
CY2021Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
34000 | USD |
CY2020Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
33000 | USD |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
89000 | USD | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
128000 | USD | |
CY2021Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
0 | USD |
CY2020Q2 | us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
94000 | USD |
us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
0 | USD | |
us-gaap |
Interest And Debt Expense
InterestAndDebtExpense
|
235000 | USD | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17964000 | USD |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6435000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-36424000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-14479000 | USD | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
9000 | USD |
CY2020Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
0 | USD |
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
-4000 | USD | |
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
0 | USD | |
CY2021Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17955000 | USD |
CY2020Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-6435000 | USD |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-36428000 | USD | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14479000 | USD | |
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17964000 | USD |
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-17964000 | USD |
CY2020Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-6435000 | USD |
CY2020Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6435000 | USD |
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-36424000 | USD | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-36424000 | USD | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14479000 | USD | |
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-14479000 | USD | |
CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.21 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.21 | |
CY2020Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.82 | |
CY2020Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.82 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-5.04 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-5.04 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-4.41 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.41 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
3285123 | shares | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
8106765 | shares |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
8106765 | shares |
CY2020Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
3538490 | shares |
CY2020Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
3538490 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7226447 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
7226447 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
3285123 | shares | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
120037000 | USD |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
0 | USD |
CY2021Q1 | mgen |
Stock Issued During Period Value Warrants Exercised Value
StockIssuedDuringPeriodValueWarrantsExercisedValue
|
940000 | USD |
CY2021Q1 | mgen |
Stock Issued During Period Value Issued For Exercise Of Stock Options And Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueIssuedForExerciseOfStockOptionsAndVestingOfRestrictedStockUnits
|
307000 | USD |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
12000 | USD |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3175000 | USD |
CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
-13000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18460000 | USD |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
105998000 | USD |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
0 | USD |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3817000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15754000 | USD |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
13000 | USD |
mgen |
Non Cash Lease Expense
NonCashLeaseExpense
|
131000 | USD | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
9000 | USD |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17964000 | USD |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
98912000 | USD |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
16000 | USD |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
664000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8044000 | USD |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27000000 | USD |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
623000 | USD |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6435000 | USD |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
21171000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-36424000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-14479000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6992000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1287000 | USD | |
mgen |
Non Cash Lease Expense
NonCashLeaseExpense
|
-1200000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
58000 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
132000 | USD | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-67000 | USD | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-481000 | USD | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-281000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2156000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-622000 | USD | |
mgen |
Increase Decrease In Unbilled Revenue Related Party
IncreaseDecreaseInUnbilledRevenueRelatedParty
|
2051000 | USD | |
mgen |
Increase Decrease In Unbilled Revenue Related Party
IncreaseDecreaseInUnbilledRevenueRelatedParty
|
0 | USD | |
mgen |
Increase Decrease In Contract With Customer Related Party Liability
IncreaseDecreaseInContractWithCustomerRelatedPartyLiability
|
779000 | USD | |
mgen |
Increase Decrease In Contract With Customer Related Party Liability
IncreaseDecreaseInContractWithCustomerRelatedPartyLiability
|
0 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1601000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-810000 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
5683000 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-2412000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26170000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
69000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-15248000 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
67381000 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
67042000 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
2000000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD | |
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
75000 | USD | |
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
1000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-333000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
2001000 | USD | |
us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
8529000 | USD | |
us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
19783000 | USD | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
218000 | USD | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1193000 | USD | |
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD | |
us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
1333000 | USD | |
us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
0 | USD | |
us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
1726000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
8311000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
18983000 | USD | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-18192000 | USD | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
5736000 | USD | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
45897000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
24846000 | USD |
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
27704000 | USD |
CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
30582000 | USD |
us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | USD | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
145000 | USD | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
120000 | USD | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | USD | |
us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | USD | |
us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
19000 | USD | |
us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-4000 | USD | |
us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | USD | |
mgen |
Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
|
0 | USD | |
mgen |
Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
|
30000 | USD | |
CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-315300000 | USD |
CY2021Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
109300000 | USD |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div> | ||
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD | |
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div> | ||
CY2020Q2 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD | |
CY2021Q2 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
CY2021Q2 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
9000.0 | USD |
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
-4000.0 | USD | |
us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | USD | |
us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
0 | USD | |
CY2020Q2 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
0 | USD |
CY2020Q2 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | USD |
us-gaap |
Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
|
0 | USD | |
CY2020Q2 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | USD |
us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | USD | |
CY2021Q2 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | USD |
us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | USD | |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
CY2021Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2048000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3752000 | USD |
CY2021Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1750000 | USD |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3443000 | USD |
CY2021Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
298000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
309000 | USD |
CY2021Q1 | us-gaap |
Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
|
142000 | USD |
CY2021Q2 | us-gaap |
Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
|
75000 | USD |
CY2021Q2 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
67000 | USD |
CY2021Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
25000 | USD |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
58000 | USD | |
CY2020Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
64000 | USD |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
132000 | USD | |
CY2021Q2 | mgen |
Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
|
10314000 | USD |
CY2020Q4 | mgen |
Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
|
5400000 | USD |
CY2021Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2566000 | USD |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1963000 | USD |
CY2021Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
412000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
455000 | USD |
CY2021Q2 | mgen |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
88000 | USD |
CY2020Q4 | mgen |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
380000 | USD |
CY2021Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
278000 | USD |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
796000 | USD |
CY2021Q2 | mgen |
Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
|
100000 | USD |
CY2020Q4 | mgen |
Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
|
100000 | USD |
CY2021Q2 | mgen |
Accrued License Agreement Liability
AccruedLicenseAgreementLiability
|
177000 | USD |
CY2020Q4 | mgen |
Accrued License Agreement Liability
AccruedLicenseAgreementLiability
|
86000 | USD |
CY2021Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
215000 | USD |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
523000 | USD |
CY2021Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
14150000 | USD |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9703000 | USD |
mgen |
Lessee Operating Lease Number Of Renewal Terms
LesseeOperatingLeaseNumberOfRenewalTerms
|
2 | renewal_term | |
CY2021Q2 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P3Y | |
CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1600000 | USD |
CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1600000 | USD |
CY2020Q1 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.06 | |
CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P12M | |
CY2021Q2 | us-gaap |
Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
|
P9M | |
CY2021Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
100000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
700000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
700000 | USD |
CY2020Q4 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.06 | |
CY2021Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1800000 | USD |
CY2021Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
412000 | USD |
CY2021Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1200000 | USD |
CY2021Q2 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
100000 | USD |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
200000 | USD | |
CY2020Q2 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
100000 | USD |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
200000 | USD | |
CY2021Q2 | mgen |
Operating Leases Operating Expense
OperatingLeasesOperatingExpense
|
34000 | USD |
mgen |
Operating Leases Operating Expense
OperatingLeasesOperatingExpense
|
68000 | USD | |
CY2020Q2 | mgen |
Operating Leases Operating Expense
OperatingLeasesOperatingExpense
|
100000 | USD |
mgen |
Operating Leases Operating Expense
OperatingLeasesOperatingExpense
|
200000 | USD | |
CY2021Q1 | mgen |
Capital Stock Shares Authorized
CapitalStockSharesAuthorized
|
205000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q1 | mgen |
Common Stock Voteper Share
CommonStockVoteperShare
|
1 | vote |
CY2021Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2021Q2 | mgen |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
|
441545 | shares |
CY2020Q4 | mgen |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
|
498500 | shares |
CY2021Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
15.94 | |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
498500 | shares |
CY2020Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
16.00 | |
mgen |
Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
|
56955 | shares | |
mgen |
Class Of Warrant Or Right Exercised In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue
|
16.50 | ||
CY2021Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
441545 | shares |
CY2021Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
15.94 | |
CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2703614 | shares |
CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2291207 | shares |
CY2021Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3817000 | USD |
CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
623000 | USD |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6992000 | USD | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1287000 | USD | |
CY2021Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
36800000 | USD |
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y5M12D | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
25827559 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
846320 | shares |